CART peptides are peptide neurotransmitters and hormones that are involved in many different physiological responses. While much is known about the peptides regarding their structure, processing and gene regulation, less is known about their postsynaptic actions and receptors. Using (125)I-CART 61-102 as a ligand and unlabeled CART 61-102 or CART 55-102 as displacers, high-affinity specific binding was detected in PC12 cells. Differentiation of the PC12 cells increased specific binding several-fold. The increase in specific binding found after differentiation was inhibited by actinomycin D and cycloheximide, suggesting that the increase in specific binding was dependent on RNA and protein synthesis. CART 1-27, a peptide that has never been shown to elicit responses, did not displace (125)I-CART 61-102 binding, nor did more than 20 other peptides that were examined. Surprisingly, however, PACAP 1-38 and PACAP 6-38 were found to be low-affinity inhibitors of CART binding. CART treatment increased binding of (35)S-GTPgamma-S to PC12 cell membranes. Moreover, CART treatment of intact PC12 cells elicited robust increases in phospho-ERK in a manner that was increased with differentiation, blocked by pertussis toxin and antagonized by PACAP 6-38. These findings extend previous research and suggest that the CART binding site in PC12 cells reflects a G protein-coupled receptor linked with Gi/o, and also demonstrate that PACAP 6-38 may be useful as a CART receptor antagonist.
CART peptides are peptide neurotranpan>smitters anpan>d hormones that are inpan>volved inpan> manpan>y different physiological responses. While much is knpan>ownpan> about the peptides regardinpan>g their structure, processinpan>g anpan>d gene regulation, less is knpan>ownpan> about their postsynpan>aptic actions anpan>d receptors. Usinpan>g (125)I-pan> class="Gene">CART 61-102 as a ligand and unlabeled CART 61-102 or CART 55-102 as displacers, high-affinity specific binding was detected in PC12 cells. Differentiation of the PC12 cells increased specific binding several-fold. The increase in specific binding found after differentiation was inhibited by actinomycin D and cycloheximide, suggesting that the increase in specific binding was dependent on RNA and protein synthesis. CART 1-27, a peptide that has never been shown to elicit responses, did not displace (125)I-CART 61-102 binding, nor did more than 20 other peptides that were examined. Surprisingly, however, PACAP 1-38 and PACAP 6-38 were found to be low-affinity inhibitors of CART binding. CART treatment increased binding of (35)S-GTPgamma-S to PC12 cell membranes. Moreover, CART treatment of intact PC12 cells elicited robust increases in phospho-ERK in a manner that was increased with differentiation, blocked by pertussis toxin and antagonized by PACAP 6-38. These findings extend previous research and suggest that the CART binding site in PC12 cells reflects a G protein-coupled receptor linked with Gi/o, and also demonstrate that PACAP 6-38 may be useful as a CART receptor antagonist.
Authors: Anita Lakatos; Steven Prinster; Aleksandra Vicentic; Randy A Hall; Michael J Kuhar Journal: Neurosci Lett Date: 2005 Aug 12-19 Impact factor: 3.046
Authors: P Gourlet; A Vandermeers; M C Vandermeers-Piret; J Rathé; P De Neef; P Robberecht Journal: Eur J Pharmacol Date: 1995-12-04 Impact factor: 4.432
Authors: M Tanida; A Hayata; N Shintani; N Yamamoto; Y Kurata; T Shibamoto; D A Morgan; K Rahmouni; H Hashimoto Journal: Neuroscience Date: 2013-02-27 Impact factor: 3.590